

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 21-814

Approved Labeling

ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from package insert and dispense with product. Dispense the capsules in the unit of use container.

Aptivus®
(tipranavir)
Capsules, 250 mg



**Boehringer
Ingelheim**

Prescribing Information

WARNING


APTIVUS CO-ADMINISTERED WITH 200 MG RITONAVIR HAS BEEN ASSOCIATED WITH REPORTS OF CLINICAL HEPATITIS AND HEPATIC DECOMPENSATION INCLUDING SOME FATALITIES. EXTRA VIGILANCE IS WARRANTED IN PATIENTS WITH CHRONIC HEPATITIS B OR HEPATITIS C CO-INFECTION, AS THESE PATIENTS HAVE AN INCREASED RISK OF HEPATOTOXICITY. (SEE WARNINGS)

DESCRIPTION

APTIVUS® (tipranavir) is the brand name for tipranavir (TPV), a non-peptidic protease inhibitor (PI) of HIV belonging to the class of 4-hydroxy-5,6-dihydro-2-pyrone sulfonamides.

APTIVUS soft gelatin capsules are for oral administration. Each capsule contains 250 mg tipranavir. The major inactive ingredients in the capsule are dehydrated alcohol (7% w/w or 0.1 g per capsule), polyoxyl 35 castor oil, propylene glycol, mono/diglycerides of caprylic/capric acid and gelatin.

The chemical name of tipranavir is 2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl). It has a molecular formula of $C_{31}H_{33}F_3N_2O_5S$ and a molecular weight of 602.7. Tipranavir has the following structural formula and is a single stereoisomer with the 1R, 6R configuration.



Tipranavir is a white to off-white to slightly yellow solid. It is freely soluble in dehydrated alcohol and propylene glycol, and insoluble in aqueous buffer at pH 7.5.

CLINICAL PHARMACOLOGY

Microbiology

Mechanism of Action

Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the virus-specific processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.

Antiviral Activity

Tipranavir inhibits the replication of laboratory strains of HIV-1 and clinical isolates in acute models of T-cell infection, with 50% effective concentrations (EC_{50}) ranging from 0.03 to 0.07 μ M (18-42 ng/mL). Tipranavir demonstrates antiviral activity *in vitro* against a broad panel of HIV-1 group M non-clade B isolates (A, C, D, F, G, H, CRF01 AE, CRF02 AG, CRF12 BF). Group O and HIV-2 isolates have reduced susceptibility *in vitro* to tipranavir with EC_{50} values ranging from 0.164 -1 μ M and 0.233-0.522 μ M, respectively. Protein binding studies have shown that the antiviral activity of tipranavir decreases on average 3.75-fold in conditions where human serum is present. When used with other antiretroviral agents *in vitro*, the combination of tipranavir was additive to antagonistic with other protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) and generally additive with the NNRTIs (delavirdine, efavirenz, and nevirapine) and the NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zidovudine). Tipranavir was synergistic with the HIV fusion inhibitor enfuvirtide. There was no antagonism of the *in vitro* combinations of tipranavir with either adefovir or ribavirin, used in the treatment of viral hepatitis.

Resistance

In vitro: HIV-1 isolates with a decreased susceptibility to tipranavir have been selected *in vitro* and obtained from patients treated with APTIVUS/ritonavir (TPV/ritonavir). HIV-1 isolates that were 87-fold resistant to tipranavir were selected *in vitro* by 9 months and contained 10 protease mutations that developed in the following order: L33F, I84V, K45I, I13V, V32I, V82L, M36I, A71V, L10F, and I54V/T. Changes in the Gag polyprotein CA/P2 cleavage site were also observed following drug selection. Experiments with site-directed mutants of HIV-1 showed that the presence of 6 mutations in the protease coding sequence (I13V, V32I, L33F, K45I, V82L, I84V) conferred > 10-fold reduced susceptibility to tipranavir. Recombinant viruses showing \geq 3-fold reduced susceptibility to tipranavir were growth impaired.

Clinical Studies of Treatment-Experienced Patients: In Phase 3 studies 1182.12 and 1182.48, multiple protease inhibitor-resistant HIV-1 isolates from 59 highly treatment-experienced patients who received APTIVUS/ritonavir and experienced virologic rebound developed amino acid substitutions that were associated with resistance to tipranavir. The most common amino acid substitutions that developed on 500/200mg APTIVUS/ritonavir in greater than 20% of APTIVUS/ritonavir virologic failure isolates were L33V/I/F, V82T, and I84V. Other substitutions that developed in 10 to 20% of APTIVUS/ritonavir virologic failure isolates included L10V/I/S, I13V, E35D/G/N, I47V, K55R, V82L, and L89V/M. Tipranavir resistance was detected at virologic rebound after an average of

38 weeks of APTIVUS/ritonavir treatment with a median 14-fold decrease in tipranavir susceptibility. The resistance profile in treatment-naïve subjects has not been characterized.

Cross-resistance

Cross-resistance among protease inhibitors has been observed. Tipranavir had < 4-fold decreased susceptibility against 90% (94/105) of HIV-1 isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir. Tipranavir-resistant viruses which emerged *in vitro* had decreased susceptibility to the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir and ritonavir but remained sensitive to saquinavir.

Baseline Genotype and Virologic Outcome Analyses

Genotypic and/or phenotypic analysis of baseline virus may aid in determining tipranavir susceptibility before initiation of APTIVUS/ritonavir therapy. Several analyses were conducted to evaluate the impact of specific mutations and mutational patterns on virologic outcome. Both the type and number of baseline protease inhibitor mutations as well as use of additional active agents (e.g., enfuvirtide) affected APTIVUS/ritonavir response rates in Phase 3 studies 1182.12 and 1182.48 through Week 24 of treatment.

Regression analyses of baseline and/or on-treatment HIV-1 genotypes from 860 highly treatment-experienced patients in Phase 2 and 3 studies demonstrated that mutations at 16 amino acid codons in the HIV protease coding sequence were associated with reduced virologic responses at 24 weeks and/or reduced tipranavir susceptibility: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D or I84V.

Analyses were also conducted to assess virologic outcome by the number of primary protease inhibitor mutations present at baseline. Response rates were reduced if five or more protease inhibitor-associated mutations were present at baseline and subjects did not receive concomitant enfuvirtide with APTIVUS/ritonavir. See Table 1.

Table 1 Phase 3 Studies 1182.12 and 1182.48: Proportion of Responders (confirmed ≥ 1 log₁₀ decrease at Week 24) by Number of Baseline Primary Protease Inhibitor (PI) Mutations

| Number of Baseline Primary PI Mutations ^a | APTIVUS/ritonavir N = 513 | | Comparator PI/ritonavir N = 502 | |
|---|------------------------------|------------------------|------------------------------------|------------------------|
| | No Enfuvirtide | + Enfuvirtide | No Enfuvirtide | + Enfuvirtide |
| Overall | 40% (147/368) | 64% (93/145) | 19% (75/390) | 30% (34/112) |
| 1 - 2 | 68% (26/38) | 75% (3/4) | 41% (17/41) | 100% (2/2) |
| 3 - 4 | 44% (78/176) | 64% (39/61) | 23% (39/170) | 40% (21/52) |
| 5+ | 28% (43/151) | 64% (51/80) | 11% (19/178) | 19% (11/57) |

^a Primary PI mutations include any amino acid change at positions 30, 32, 36, 46, 47, 48, 50, 53, 54, 82, 84, 88 and 90

The median change from baseline in HIV-1 RNA at weeks 2, 4, 8, 16 and 24 was evaluated by the number of baseline primary protease inhibitor mutations (1-4 or ≥ 5) in subjects who received APTIVUS/ritonavir with or without enfuvirtide. The following observations were made:

- Approximately 1.5 \log_{10} decrease in HIV-1 RNA at early time points (Week 2) regardless of the number of baseline primary protease inhibitor mutations (1-4 or 5+).
- Subjects with 5 or more primary protease inhibitor mutations in their HIV-1 at baseline who received APTIVUS/ritonavir without enfuvirtide (n=204) began to lose their antiviral response after Week 4.
- Early HIV-1 RNA decreases (1.5–2 \log_{10}) were sustained through Week 24 in subjects with 5 or more primary protease inhibitor mutations at baseline who received enfuvirtide with APTIVUS/ritonavir (n=88).

Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change pending additional data.

Baseline Phenotype and Virologic Outcome Analyses

APTIVUS/ritonavir response rates were also assessed by baseline tipranavir phenotype. Relationships between baseline phenotypic susceptibility to tipranavir, mutations at protease amino acid codons 33, 82, 84 and 90, tipranavir resistance-associated mutations, and response to APTIVUS/ritonavir therapy at Week 24 are summarized in Table 2. These baseline phenotype groups are not meant to represent clinical susceptibility breakpoints for APTIVUS/ritonavir because the data are based on the select 1182.12 and 1182.48 patient population. The data are provided to give clinicians information on the likelihood of virologic success based on pre-treatment susceptibility to APTIVUS/ritonavir in highly protease inhibitor-experienced patients.

Table 2 Response by Baseline Tipranavir Phenotype in the 1182.12 and 1182.48 Trials

| Baseline Tipranavir Phenotype (Fold Change) ^a | Proportion of Responders ^b with No Enfuvirtide Use | Proportion of Responders ^b with ENF Use | # of Baseline Protease Mutations at 33, 82, 84, 90 | # of Baseline Tipranavir Resistance-Associated Mutations ^c | Tipranavir Susceptibility |
|--|---|--|--|---|---------------------------|
| 0-3 | 45% (74/163) | 77% (46/60) | 0-2 | 0-4 | Susceptible |
| > 3-10 | 21% (10/47) | 43% (12/28) | 3 | 5-7 | Decreased Susceptibility |
| > 10 | 0% (0/8) | 57% (4/7) | 4 | 8+ | Resistant |

^a Change in tipranavir IC₅₀ value from wild-type reference

^b Confirmed $\geq 1 \log_{10}$ decrease at Week 24

^c Number of amino acid substitutions in HIV protease among L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D or I84V

Pharmacodynamics


The median Inhibitory Quotient (IQ) determined from 301 highly treatment-experienced patients was about 75 (inter-quartile range: 29-189), from pivotal clinical trials 1182.12 and 1182.48. The IQ is defined as the tipranavir trough concentration divided by the viral IC_{50} value, corrected for protein binding. There was a relationship between the proportion of patients with a $\geq 1 \log_{10}$ reduction of viral load from baseline at week 24 and their IQ value. Among the 206 patients receiving APTIVUS/ritonavir without enfuvirtide, the response rate was 23% in those with an IQ value < 75 and 55% in those with an IQ value ≥ 75 . Among the 95 patients receiving APTIVUS/ritonavir with enfuvirtide, the response rates in patients with an IQ value < 75 versus those with an IQ value ≥ 75 were 43% and 84%, respectively. These IQ groups are derived from a select population and are not meant to represent clinical breakpoints.

Pharmacokinetics in Adult Patients

In order to achieve effective tipranavir plasma concentrations and a twice-daily dosing regimen, co-administration of APTIVUS with 200 mg of ritonavir is essential (see **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**). Ritonavir inhibits hepatic cytochrome P450 3A (CYP 3A), the intestinal P-glycoprotein (P-gp) efflux pump and possibly intestinal CYP 3A. In a dose-ranging evaluation in 113 HIV-negative male and female volunteers, there was a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations of tipranavir following tipranavir co-administered with low-dose ritonavir (500/200 mg twice daily) compared to tipranavir 500 mg twice daily without ritonavir.

Figure 1 displays mean plasma concentrations of tipranavir and ritonavir at steady state for the 500/200 mg tipranavir/ritonavir dose.

Figure 1 Mean Steady State Tipranavir Plasma Concentrations (95% CI) with Ritonavir Co-administration (tipranavir/ritonavir 500/200 mg BID)



Absorption and Bioavailability

Absorption of tipranavir in humans is limited, although no absolute quantification of absorption is available. Tipranavir is a P-gp substrate, a weak P-gp inhibitor, and appears to be a potent P-gp inducer as well. *In vivo* data suggest that the net effect of tipranavir/ritonavir at the proposed dose regimen (500/200 mg) is P-gp induction at steady-state, although ritonavir is a P-gp inhibitor. Tipranavir trough concentrations at steady-state are about 70% lower than those on Day 1, presumably due to intestinal P-gp induction. Steady state is attained in most subjects after 7-10 days of dosing.

Dosing with APTIVUS 500 mg concomitant with 200 mg ritonavir twice-daily for greater than 2 weeks and without meal restriction produced the following pharmacokinetic parameters for female and male HIV-positive patients. See Table 3.

Table 3 Pharmacokinetic Parameters^a of tipranavir/ritonavir 500/200 mg for HIV+ Patients by Gender

| | Females (n = 14) | Males (n = 106) |
|-----------------------------|---------------------|--------------------|
| C _{ptrough} (μM) | 41.6 ± 24.3 | 35.6 ± 16.7 |
| C _{max} (μM) | 94.8 ± 22.8 | 77.6 ± 16.6 |
| T _{max} (h) | 2.9 | 3.0 |
| AUC _{0-12h} (μM•h) | 851 ± 309 | 710 ± 207 |
| CL (L/h) | 1.15 | 1.27 |
| V (L) | 7.7 | 10.2 |
| t _{1/2} (h) | 5.5 | 6.0 |

^a Population pharmacokinetic parameters reported as mean ± standard deviation

Effects of Food on Oral Absorption

APTIVUS capsules co-administered with ritonavir should be taken with food. Bioavailability is increased with a high fat meal. Tipranavir capsules, administered under high fat meal conditions or with a light snack of toast and skimmed milk, were tested in a multiple dose study. High-fat meals (868 kcal, 53% derived from fat, 31% derived from carbohydrates) enhanced the extent of bioavailability (AUC point estimate 1.31, confidence interval 1.23-1.39), but had minimal effect on peak tipranavir concentrations (C_{max} point estimate 1.16, confidence interval 1.09-1.24).

When APTIVUS, co-administered with low-dose ritonavir, was co-administered with 20 mL of aluminum and magnesium-based liquid antacid, tipranavir AUC_{12h}, C_{max} and C_{12h} were reduced by 25-29%. Consideration should be given to separating tipranavir/ritonavir dosing from antacid administration to prevent reduced absorption of tipranavir.

Distribution

Tipranavir is extensively bound to plasma proteins (> 99.9%). It binds to both human serum albumin and α -1-acid glycoprotein. The mean fraction of APTIVUS (dosed without ritonavir) unbound in plasma was similar in clinical samples from healthy volunteers ($0.015\% \pm 0.006\%$) and HIV-positive patients ($0.019\% \pm 0.076\%$). Total plasma tipranavir concentrations for these samples ranged from 9 to 82 μ M. The unbound fraction of tipranavir appeared to be independent of total drug concentration over this concentration range.

No studies have been conducted to determine the distribution of tipranavir into human cerebrospinal fluid or semen.

Metabolism

In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.

The oral clearance of tipranavir decreased after the addition of ritonavir, which may represent diminished first-pass clearance of the drug at the gastrointestinal tract as well as the liver.

The metabolism of tipranavir in the presence of 200 mg ritonavir is minimal. Administration of 14 C-tipranavir to subjects that received tipranavir/ritonavir 500/200 mg dosed to steady-state demonstrated that unchanged tipranavir accounted for 98.4% or greater of the total plasma radioactivity circulating at 3, 8, or 12 hours after dosing. Only a few metabolites were found in plasma, and all were at trace levels (0.2% or less of the plasma radioactivity). In feces, unchanged tipranavir represented the majority of fecal radioactivity (79.9% of fecal radioactivity). The most abundant fecal metabolite, at 4.9% of fecal radioactivity (3.2% of dose), was a hydroxyl metabolite of tipranavir. In urine, unchanged tipranavir was found in trace amounts (0.5% of urine radioactivity). The most abundant urinary metabolite, at 11.0% of urine radioactivity (0.5% of dose) was a glucuronide conjugate of tipranavir.

Elimination

Administration of 14 C-tipranavir to subjects (n=8) that received tipranavir/ritonavir 500/200 mg dosed to steady-state demonstrated that most radioactivity (median 82.3%) was excreted in feces, while only a median of 4.4% of the radioactive dose administered was recovered in urine. In addition, most radioactivity (56%) was excreted between 24 and 96 hours after dosing. The effective mean elimination half-life of tipranavir/ritonavir in healthy volunteers (n=67) and HIV-infected adult patients (n=120) was approximately 4.8 and 6.0 hours, respectively, at steady state following a dose of 500/200 mg twice daily with a light meal.

Pharmacokinetics in Special Populations***Renal Impairment***

APTIVUS pharmacokinetics has not been studied in patients with renal dysfunction. However, since the renal clearance of tipranavir is negligible, a decrease in total body clearance is not expected in patients with renal insufficiency.

Hepatic Impairment

In a study comparing 9 patients with mild (Child-Pugh A) hepatic impairment to 9 controls, the single and multiple dose plasma concentrations of tipranavir and ritonavir were increased in patients with hepatic impairment, but were within the range observed in clinical trials. No dosing adjustment is required in patients with mild hepatic impairment.

The influence of moderate hepatic impairment (Child-Pugh B) or severe hepatic impairment (Child-Pugh C) on the multiple-dose pharmacokinetics of tipranavir administered with ritonavir has not been evaluated (see **DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS**).

Gender

Evaluation of steady-state plasma tipranavir trough concentrations at 10-14 h after dosing from the 1182.12 and 1182.48 studies demonstrated that females generally had higher tipranavir concentrations than males. After 4 weeks of tipranavir/ritonavir 500/200 mg BID, the median plasma trough concentration of tipranavir was 43.9 μM for females and 31.1 μM for males. The difference in concentrations does not warrant a dose adjustment.

Race

Evaluation of steady-state plasma tipranavir trough concentrations at 10-14 h after dosing from the 1182.12 and 1182.48 studies demonstrated that white males generally had more variability in tipranavir concentrations than black males, but the median concentration and the range making up the majority of the data are comparable between the races.

Geriatric Patients

Evaluation of steady-state plasma tipranavir trough concentrations at 10-14 h after dosing from the 1182.12 and 1182.48 studies demonstrated that there was no change in median trough tipranavir concentrations as age increased for either gender through 65 years of age. There were an insufficient number of women greater than age 65 years in the two trials to evaluate the elderly, but the trend of consistent trough tipranavir concentrations with increasing age through 80 years for men was supported.

Pediatric Patients

The pharmacokinetic profile of tipranavir in pediatric patients has not been established.

Drug Interactions

See also **CONTRAINDICATIONS, WARNINGS and PRECAUTIONS, Drug Interactions**.

APTIVUS co-administered with 200 mg of ritonavir can alter plasma exposure of other drugs and other drugs may alter plasma exposure of tipranavir.

Potential for tipranavir/ritonavir to Affect Other Drugs

1. APTIVUS co-administered with 200 mg of ritonavir at the recommended dose, is a net inhibitor of CYP 3A and may increase plasma concentrations of agents that are primarily metabolized by CYP 3A. Thus, co-administration of APTIVUS/ritonavir with drugs highly dependent on CYP 3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events should be contraindicated. Co-administration with other CYP 3A substrates may require a dose adjustment or additional monitoring (see **CONTRAINDICATIONS** and **PRECAUTIONS**).
2. Studies in human liver microsomes indicated tipranavir is an inhibitor of CYP 1A2, CYP 2C9, CYP 2C19 and CYP 2D6. The potential net effect of tipranavir/ritonavir on CYP 2D6 is inhibition, because ritonavir is a CYP 2D6 inhibitor. The *in vivo* net effect of tipranavir administered with ritonavir on CYP 1A2, CYP 2C9 and CYP 2C19 is not known. Data are not available to indicate whether tipranavir inhibits or induces glucuronosyl transferases and whether tipranavir induces CYP 1A2, CYP 2C9 and CYP 2C19.
3. Tipranavir is a P-gp substrate, a weak P-gp inhibitor, and appears to be a potent P-gp inducer as well. Data suggest that the net effect of tipranavir co-administered with 200 mg of ritonavir is P-gp induction at steady-state, although ritonavir is a P-gp inhibitor.
4. It is difficult to predict the net effect of APTIVUS administered with ritonavir on oral bioavailability and plasma concentrations of drugs that are dual substrates of CYP 3A and P-gp. The net effect will vary depending on the relative affinity of the co-administered drugs for CYP 3A and P-gp, and the extent of intestinal first-pass metabolism/efflux.

Potential for Other Drugs to Affect tipranavir

1. Tipranavir is a CYP 3A substrate and a P-gp substrate. Co-administration of APTIVUS/ritonavir and drugs that induce CYP 3A and/or P-gp may decrease tipranavir plasma concentrations. Co-administration of APTIVUS/ritonavir and drugs that inhibit P-gp may increase tipranavir plasma concentrations.
2. Co-administration of APTIVUS/ritonavir with drugs that inhibit CYP 3A may not further increase tipranavir plasma concentrations, because the level of metabolites is low following steady-state administration of APTIVUS/ritonavir 500/200 mg twice daily.

Drug interaction studies were performed with APTIVUS, co-administered with 200 mg of ritonavir, and other drugs likely to be co-administered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of co-administration of APTIVUS with 200 mg ritonavir, on the AUC, C_{max} and C_{min} , are summarized in Tables 4 and 5. For information regarding clinical recommendations (see **PRECAUTIONS**, **Drug Interactions**, **Tables 8** and **9**).

Table 4 Drug Interactions: Pharmacokinetic Parameters for Tipranavir in the Presence of Co-administered Drugs

| Co-administered Drug | Co-administered Drug Dose (Schedule) | TPV/ritonavir Drug Dose (Schedule) | n | PK | Ratio (90% Confidence Interval) of Tipranavir Pharmacokinetic Parameters with/without Co-administered Drug; No Effect = 1.00 | | |
|----------------------------------|--------------------------------------|------------------------------------|---------|----|--|-------------------|-------------------|
| | | | | | C _{max} | AUC | C _{min} |
| Atorvastatin | 10 mg (1 dose) | 500/200 mg BID (14 doses) | 22 | ↔ | 0.96 (0.86, 1.07) | 1.08 (1.00, 1.15) | 1.04 (0.89, 1.22) |
| Clarithromycin | 500 mg BID (25 doses) | 500/200 mg BID* | 24(68) | ↑ | 1.40 (1.24, 1.47) | 1.66 (1.43, 1.73) | 2.00 (1.58, 2.47) |
| Didanosine | 400 mg (1 dose) | 500/100 mg BID (27 doses) | 5 | ↓ | 1.32 (1.09, 1.60) | 1.08 (0.82, 1.42) | 0.66 (0.31, 1.43) |
| Efavirenz | 600 mg QD (8 doses) | 500/100 mg BID* | 21(89) | ↓ | 0.79 (0.69, 0.89) | 0.69 (0.57, 0.83) | 0.58 (0.36, 0.86) |
| | | 750/200 mg BID* | 25(100) | ↔ | 0.97 (0.85, 1.09) | 1.01 (0.85, 1.18) | 0.97 (0.69, 1.28) |
| Ethinyl estradiol /Norethindrone | 0.035/1.0 mg (1 dose) | 500/100 mg BID (21 doses) | 21 | ↓ | 1.10 (0.98, 1.24) | 0.98 (0.88, 1.11) | 0.73 (0.59, 0.90) |
| | | 750/200 mg BID (21 doses) | 13 | ↔ | 1.01 (0.96, 1.06) | 0.98 (0.90, 1.07) | 0.91 (0.69, 1.20) |
| Fluconazole | 100 mg QD (12 dose) | 500/200 mg BID* | 20(68) | ↑ | 1.32 (1.18, 1.47) | 1.50 (1.29, 1.73) | 1.69 (1.33, 2.09) |
| Loperamide | 16 mg (1 dose) | 750/200 mg BID (21 doses) | 24 | ↓ | 1.03 (0.92, 1.17) | 0.98 (0.86, 1.12) | 0.74 (0.62, 0.88) |
| Rifabutin | 150 mg (1 dose) | 500/200 mg BID (15 doses) | 21 | ↔ | 0.99 (0.93, 1.07) | 1.00 (0.96, 1.04) | 1.16 (1.07, 1.27) |
| Tenofovir | 300 mg (1 dose) | 500/100 mg BID | 22 | ↓ | 0.83 (0.74, 0.94) | 0.82 (0.75, 0.91) | 0.79 (0.70, 0.90) |
| | | 750/200 mg BID (23 doses) | 20 | ↔ | 0.89 (0.84, 0.96) | 0.91 (0.85, 0.97) | 0.88 (0.78, 1.00) |
| Zidovudine | 300 mg (1 dose) | 500/100 mg BID | 29 | ↓ | 0.87 (0.80, 0.94) | 0.82 (0.76, 0.89) | 0.77 (0.68, 0.87) |
| | | 750/200 mg BID (23 doses) | 25 | ↔ | 1.02 (0.94, 1.10) | 1.02 (0.92, 1.13) | 1.07 (0.86, 1.34) |

*steady state comparison to historical data

Table 5 Drug Interactions: Pharmacokinetic Parameters for Co-administered Drug in the Presence of tipranavir/ritonavir

| Co-administered Drug | Co-administered Drug Dose (Schedule) | TPV/ritonavir Drug Dose (Schedule) | n | PK | Ratio (90% Confidence Interval) of Co-administered Drug Pharmacokinetic Parameters with/without TPV/ritonavir; No Effect = 1.00 | | |
|-----------------------------|---|------------------------------------|------------|----|---|--------------------------------|--------------------------------|
| | | | | | C _{max} | AUC | C _{min} |
| Amprenavir/RTV ^a | 600/100 mg BID (27 doses) | 500/200 mg BID (28 doses) | 16 | ↓ | 0.61 (0.51, 0.73) ^d | 0.56 (0.49, 0.64) ^d | 0.45 (0.38, 0.53) ^d |
| | | | 74 | ↓ | - | - | 0.44 (0.39, 0.49) ^e |
| Abacavir ^a | 300 mg BID (43 doses) | 250/200 mg BID | 28 | ↓ | 0.56 (0.48, 0.66) | 0.56 (0.49, 0.63) | - |
| | | 750/100 mg BID | 14 | ↓ | 0.54 (0.47, 0.63) | 0.64 (0.55, 0.74) | - |
| | | 1250/100 mg BID (42 doses) | 11 | ↓ | 0.48 (0.42, 0.53) | 0.65 (0.55, 0.76) | - |
| Atorvastatin | 10 mg (1 dose) | 500/200 mg BID (17 doses) | 22 | ↑ | 8.61 (7.25, 10.21) | 9.36 (8.02, 10.94) | 5.19 (4.21, 6.40) |
| Orthohydroxy-atorvastatin | | | 21, 12, 17 | ↓ | 0.02 (0.02, 0.03) | 0.11 (0.08, 0.17) | 0.07 (0.06, 0.08) |
| Parahydroxy-atorvastatin | | | 13, 22, 1 | ↓ | 1.04 (0.87, 1.25) | 0.18 (0.14, 0.24) | 0.33 (NA) |
| Clarithromycin | 500 mg BID (25 doses) | 500/200 mg BID (15 doses) | 21 | ↑ | 0.95 (0.83, 1.09) | 1.19 (1.04, 1.37) | 1.68 (1.42, 1.98) |
| 14-OH-clarithromycin | | | 21 | ↓ | 0.03 (0.02, 0.04) | 0.03 (0.02, 0.04) | 0.05 (0.04, 0.07) |
| Didanosine ^b | 200 mg BID, ≥60 kg | 250/200 mg BID | 10 | ↓ | 0.57 (0.42, 0.79) | 0.67 (0.51, 0.88) | - |
| | | 750/100 mg BID | 8 | ↔ | 0.76 (0.49, 1.17) | 0.97 (0.64, 1.47) | - |
| | | 1250/100 mg BID (42 doses) | 9 | ↔ | 0.77 (0.47, 1.26) | 0.87 (0.47, 1.65) | - |
| | 400 mg (1 dose) | 500/100 mg BID (27 doses) | 5 | ↔ | 0.80 (0.63, 1.02) | 0.90 (0.72, 1.11) | 1.17 (0.62, 2.20) |
| Efavirenz ^b | 600 mg QD (15 doses) | 500/100 mg BID | 24 | ↔ | 1.09 (0.99, 1.19) | 1.04 (0.97, 1.12) | 1.02 (0.92, 1.12) |
| | | 750/200 mg BID (15 doses) | 22 | ↔ | 1.12 (0.98, 1.28) | 1.00 (0.93, 1.09) | 0.94 (0.84, 1.04) |
| Ethinyl estradiol | 0.035 mg (1 dose) | 500/100 mg BID | 21 | ↓ | 0.52 (0.47, 0.57) | 0.52 (0.48, 0.56) | - |
| | | 750/200 mg BID (21 doses) | 13 | ↓ | 0.48 (0.42, 0.57) | 0.57 (0.54, 0.60) | - |
| Fluconazole | 200 mg (Day 1) then 100 mg QD (6 or 12 doses) | 500/200 mg BID (2 or 14 doses) | 19 | ↔ | 0.97 (0.94, 1.01) | 0.99 (0.97, 1.02) | 0.98 (0.94, 1.02) |
| | | | 19 | ↔ | 0.94 (0.91, 0.98) | 0.92 (0.88, 0.95) | 0.89 (0.85, 0.92) |
| Lopinavir/RTV ^a | 400/100 mg BID (27 doses) | 500/200 mg BID (28 doses) | 21 | ↓ | 0.53 (0.40, 0.69) ^d | 0.45 (0.32, 0.63) ^d | 0.30 (0.17, 0.51) ^d |
| | | | 69 | ↓ | - | - | 0.48 (0.40, 0.58) ^c |
| Loperamide | 16 mg (1 dose) | 750/200 mg BID (21 doses) | 24 | ↓ | 0.39 (0.31, 0.48) | 0.49 (0.40, 0.61) | - |
| N-Demethyl-Loperamide | | | 24 | ↓ | 0.21 (0.17, 0.25) | 0.23 (0.19, 0.27) | |

^aHIV+ patients

^bHIV+ patients (TPV/ritonavir 250 mg/200 mg, 750 mg/200 mg and 1250 mg/100 mg) and healthy volunteers (TPV/ritonavir 500 mg/100 mg and 750 mg/200 mg)

^cNormalized sum of parent drug (rifabutin) and active metabolite (25-O-desacetyl-rifabutin)

^dIntensive PK analysis

^eDrug levels obtained at 8-16 hrs post-dose

Table 5 Drug Interactions: Pharmacokinetic Parameters for Co-administered Drug in the Presence of tipranavir/ritonavir (continued)

| Co-administered Drug | Co-administered Drug Dose (Schedule) | TPV/ritonavir Drug Dose (Schedule) | n | PK | Ratio (90% Confidence Interval) of Co-administered Drug Pharmacokinetic Parameters with/without TPV/ritonavir No Effect = 1.00 | | |
|---|--------------------------------------|------------------------------------|----|----|---|--------------------------------|------------------------------|
| | | | | | C _{max} | AUC | C _{min} |
| Lamivudine ^a | 150 mg BID (43 doses) | 250/200 mg BID | 64 | ↔ | 0.96 (0.89, 1.03) | 0.95 (0.89, 1.02) | - |
| | | 750/100 mg BID | 46 | ↔ | 0.86 (0.78, 0.94) | 0.96 (0.90, 1.03) | - |
| | | 1250/100 mg BID (42 doses) | | | | | |
| | | | 35 | ↔ | 0.71 (0.62, 0.81) | 0.82 (0.66, 1.00) | - |
| Nevirapine ^a | 200 mg BID (43 doses) | 250/200 mg BID | 26 | ↔ | 0.97 (0.90, 1.04) | 0.97 (0.91, 1.04) | 0.96 (0.87, 1.05) |
| | | 750/100 mg BID | 22 | ↔ | 0.86 (0.76, 0.97) | 0.89 (0.78, 1.01) | 0.93 (0.80, 1.08) |
| | | 1250/100 mg BID (42 doses) | 17 | ↔ | 0.71 (0.62, 0.82) | 0.76 (0.63, 0.91) | 0.77 (0.64, 0.92) |
| Norethindrone | 1.0 mg (1 dose) | 500/100 mg BID | 21 | ↔ | 1.03 (0.94, 1.13) | 1.14 (1.06, 1.22) | - |
| | | 750/200 mg BID (21 doses) | 13 | ↔ | 1.08 (0.97, 1.20) | 1.27 (1.13, 1.43) | - |
| Rifabutin | 150 mg (1 dose) | 500/200 mg BID (15 doses) | 20 | ↑ | 1.70 (1.49, 1.94) | 2.90 (2.59, 3.26) | 2.14 (1.90, 2.41) |
| 25-O-desacetyl-rifabutin | | | 20 | ↑ | 3.20 (2.78, 3.68) | 20.71 (17.66, 24.28) | 7.83 (6.70, 9.14) |
| Rifabutin + 25-O-desacetyl-rifabutin ^c | | | 20 | ↑ | 1.86 (1.63, 2.12) | 4.33 (3.86, 4.86) | 2.76 (2.44, 3.12) |
| Saquinavir/RTV ^a | 600/100 mg BID (27 doses) | 500/200 mg BID (28 doses) | 20 | ↓ | 0.30 (0.23, 0.40) ^d | 0.24 (0.19, 0.32) ^d | 0.18(0.13,0.26) ^d |
| | | | 68 | ↓ | - | - | 0.20(0.16,0.25) ^e |
| Stavudine ^a | 40 mg BID, ≥60 kg | 250/200 mg BID | 26 | ↔ | 0.90 (0.81, 1.02) | 1.00 (0.91, 1.11) | - |
| | | 750/100 mg BID | 22 | ↔ | 0.76 (0.66, 0.89) | 0.84 (0.74, 0.96) | - |
| | | 1250/100 mg BID (42 doses) | 19 | ↔ | 0.74 (0.69, 0.80) | 0.93 (0.83, 1.05) | - |
| Tenofovir | 300 mg (1 dose) | 500/100 mg BID | 22 | ↓ | 0.77 (0.68, 0.87) | 0.98 (0.91, 1.05) | 1.07 (0.98, 1.17) |
| | | 750/200 mg BID (23 doses) | 20 | ↓ | 0.62 (0.54, 0.71) | 1.02 (0.94, 1.10) | 1.14 (1.01, 1.27) |
| Zidovudine ^b | 300 mg BID (43 doses) | 250/200 mg BID | 48 | ↓ | 0.54 (0.47, 0.62) | 0.58 (0.51, 0.66) | - |
| | | 750/100 mg BID | 31 | ↓ | 0.51 (0.44, 0.60) | 0.64 (0.55, 0.75) | - |
| | | 1250/100 mg BID (42 doses) | 23 | ↓ | 0.49 (0.40, 0.59) | 0.69 (0.49, 0.97) | - |
| | 300 mg (1 dose) | 500/100 mg BID | 29 | ↓ | 0.39 (0.33, 0.45) | 0.57 (0.52, 0.63) | 0.89 (0.81, 0.99) |
| | | 750/200 mg BID (23 doses) | 25 | □ | 0.44 (0.36, 0.54) | 0.67 (0.62, 0.73) | 1.25 (1.08, 1.44) |
| Zidovudine glucuronide | | 500/100 mg BID | 29 | ↑ | 0.82 (0.74, 0.90) | 1.02 (0.97, 1.06) | 1.52 (1.34, 1.71) |
| | | 750/200 mg BID (23 doses) | 25 | ↑ | 0.82 (0.73, 0.92) | 1.09 (1.05, 1.14) | 1.94 (1.62, 2.31) |

^aHIV+ patients

^bHIV+ patients (TPV/ritonavir 250 mg/200 mg, 750 mg/200 mg and 1250 mg/100 mg) and healthy volunteers (TPV/ritonavir 500 mg/100 mg and 750 mg/200 mg)

^cNormalized sum of parent drug (rifabutin) and active metabolite (25-O-desacetyl-rifabutin)

^dIntensive PK analysis

^eDrug levels obtained at 8-16 hrs post-dose

INDICATIONS AND USAGE

APTIVUS® (tipranavir), co-administered with 200 mg of ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 24 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with APTIVUS/ritonavir:

- The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response (see **CLINICAL PHARMACOLOGY, Microbiology and INDICATIONS AND USAGE, Description of Clinical Studies**).
- Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir (see **CLINICAL PHARMACOLOGY, Microbiology**). The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir (see **CLINICAL PHARMACOLOGY, Microbiology**).
- Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment (see **WARNINGS**).
- Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or other underlying hepatic impairment (see **WARNINGS**).
- The extensive drug-drug interaction potential of APTIVUS/ritonavir when co-administered with multiple classes of drugs must be considered prior to and during APTIVUS/ritonavir use (see **CLINICAL PHARMACOLOGY and CONTRAINDICATIONS**).
- The risk-benefit of APTIVUS/ritonavir has not been established in treatment-naïve adult patients or pediatric patients.

There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1.

Description of Clinical Studies

The following clinical data is derived from analyses of 24-week data from ongoing studies measuring effects on plasma HIV-1 RNA levels and CD4+ cell counts. At present there are no results from controlled studies evaluating the effect of APTIVUS/ritonavir on clinical progression of HIV.

Treatment-Experienced Patients

Studies 1182.12 and 1182.48: APTIVUS/ritonavir 500/200 mg BID + optimized background regimen (OBR) vs. Comparator Protease Inhibitor/ritonavir BID + OBR

Studies 1182.12 and 1182.48 are ongoing, randomized, controlled, open-label, multicenter studies in HIV-positive, triple antiretroviral class experienced patients. All patients were required to have previously received at least two protease inhibitor-based antiretroviral regimens and were failing a protease inhibitor-based regimen at the time of study entry with baseline HIV-1 RNA at least 1000 copies/mL and any CD4+ cell count. At least one primary protease gene mutation from among 30N, 46I, 46L, 48V, 50V, 82A, 82F, 82L, 82T, 84V or 90M had to be present at baseline, with not more than two mutations at codons 33, 82, 84 or 90.

These studies evaluated treatment response at 24 weeks in a total of 1159 patients receiving either APTIVUS co-administered with 200 mg of ritonavir plus OBR versus a control group receiving a ritonavir-boosted protease inhibitor (lopinavir, amprenavir, saquinavir or indinavir) plus OBR. Prior to randomization, OBR was individually defined for each patient based on genotypic resistance testing and patient history. The investigator had to declare OBR, comparator protease inhibitor, and use of enfuvirtide prior to randomization. Randomization was stratified by choice of comparator protease inhibitor and use of enfuvirtide.

After Week 8, patients in the control group who met the protocol defined criteria of initial lack of virologic response had the option of discontinuing treatment and switching over to APTIVUS/ritonavir in a separate roll-over study.

Demographics and baseline characteristics were balanced between the APTIVUS/ritonavir arm and control arm. In both studies combined, the 1159 patients had a median age of 43 years (range 17-80), were 88% male, 73% white, 14% black and 1% Asian. The median baseline plasma HIV-1 RNA was 4.82 (range 2 to 6.8) \log_{10} copies/mL and median baseline CD4+ cell count was 155 (range 1 to 1893) cells/mm³. Forty percent (40%) of the patients had baseline HIV-1 RNA of $\geq 100,000$ copies/mL, 61% had a baseline CD4+ cell count < 200 cells/mm³, and 57% had experienced an AIDS defining Class C event at baseline.

Patients had prior exposure to a median of 6 NRTIs, 1 NNRTI, and 4 PIs. A total of 12% of patients had previously used enfuvirtide. In baseline patient samples (n=454), 97% of the isolates were resistant to at least one protease inhibitor, 95% of the isolates were resistant to at least one NRTI, and $> 75\%$ of the isolates were resistant to at least one NNRTI.

The individually pre-selected protease inhibitor based on genotypic testing and the patient's medical history was lopinavir in 50%, amprenavir in 26%, saquinavir in 20% and indinavir in 4% of patients. A total of 86% were possibly resistant or resistant to the pre-selected comparator protease inhibitors. Approximately 25% of patients used enfuvirtide during study. There were differences between Studies 1182.12 and 1182.48 in the use of the protease inhibitors and in the use of enfuvirtide.

Treatment response and efficacy outcomes of randomized treatment through Week 24 of Studies 1182.12 and 1182.48 are shown in Table 6.

Table 6 Outcomes of Randomized Treatment Through Week 24 (Pooled Studies 1182.12 and 1182.48)

| Outcome | Tipranavir/ritonavir (500/200 mg BID) + OBR (N = 582) | Comparator Protease Inhibitor*/ritonavir + OBR (N = 577) |
|---|---|--|
| Virological Responders ^a (confirmed at least 1 log ₁₀ HIV-1 RNA below baseline) | 40% | 18% |
| Virological failures | 54% | 79% |
| Initial lack of virologic response by Week 8 ^b | 35% | 59% |
| Rebound | 12% | 11% |
| Never suppressed | 7% | 8% |
| Death ^c or discontinued due to adverse events | 1% | 1% |
| Discontinued due to other reasons ^d | 5% | 2% |

*Comparator protease inhibitors were lopinavir, amprenavir, saquinavir or indinavir and 86% of patients were possibly resistant or resistant to the chosen protease inhibitors.

^aPatients achieved and maintained a confirmed ≥ 1 log₁₀ HIV-1 RNA drop from baseline through Week 24 without prior evidence of treatment failure.

^bPatients did not achieve a 0.5 log₁₀ HIV-1 RNA drop from baseline and did not have viral load < 100,000 copies/mL by Week 8.

^cPatients who died while being virologically suppressed.

^dIncludes patients who were lost to-follow-up, withdrawn consent, non-adherent, protocol violations, added/changed background antiretroviral drugs for reasons other than tolerability or toxicity, or discontinued while suppressed.

Through 24 weeks of treatment, the proportion of patients in the APTIVUS/ritonavir arm compared to the comparator PI/ritonavir arm with HIV-1 RNA < 400 copies/mL was 34% and 16% respectively, and with HIV-1 RNA < 50 copies/mL was 23% and 9% respectively. Among all randomized and treated patients, the median change from baseline in HIV-1 RNA at the last measurement up to Week 24 was -0.80 log₁₀ copies/mL in patients receiving APTIVUS/ritonavir versus -0.25 log₁₀ copies/mL in the comparator PI/ritonavir arm.

Among all randomized and treated patients, the median change from baseline in CD4+ cell count at the last measurement up to Week 24 was +34 cells/mm³ in patients receiving tipranavir/ritonavir (N = 582) versus +4 cells/mm³ in the comparator PI/ritonavir (N = 577) arm.

Patients in the APTIVUS/ritonavir arm achieved a significantly better virologic outcome when APTIVUS/ritonavir was combined with enfuvirtide (see **CLINICAL PHARMACOLOGY, Microbiology**).

CONTRAINDICATIONS

APTIVUS (tipranavir) is contraindicated in patients with known hypersensitivity to any of the ingredients of the product.

APTIVUS is contraindicated in patients with moderate and severe (Child-Pugh Class B and C, respectively) hepatic insufficiency (see **WARNINGS**).

Co-administration of APTIVUS with 200 mg of ritonavir with drugs that are highly dependent on CYP 3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. These drugs are listed in Table 7 below. For information regarding clinical recommendations see **PRECAUTIONS, Drug Interactions, Tables 8 and 9.**

Table 7 Drugs that are Contraindicated with Tipranavir, Co-Administered with 200 mg of Ritonavir

| Drug Class | Drugs within Class that are Contraindicated with APTIVUS, Co-administered with 200 mg of ritonavir |
|---------------------|---|
| Antiarrhythmics | Amiodarone, bepridil, flecainide, propafenone, quinidine |
| Antihistamines | Astemizole, terfenadine |
| Ergot derivatives | Dihydroergotamine, ergonovine, ergotamine, methylergonovine |
| GI motility agent | Cisapride |
| Neuroleptic | Pimozide |
| Sedatives/hypnotics | Midazolam, triazolam |

Due to the need for co-administration of APTIVUS with 200 mg of ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.

WARNINGS

ALERT: Find out about medicines that should NOT be taken with APTIVUS. This statement is included on the product's bottle label.

APTIVUS (tipranavir) must be co-administered with 200 mg of ritonavir to exert its therapeutic effect (see **DOSAGE AND ADMINISTRATION**). Failure to correctly co-administer APTIVUS with ritonavir will result in reduced plasma levels of tipranavir that will be insufficient to achieve the desired antiviral effect and will alter some drug interactions (effect of tipranavir and ritonavir on other drugs).

Please refer to ritonavir prescribing information for additional information on precautionary measures.

Hepatic Impairment and Toxicity

APTIVUS co-administered with 200 mg of ritonavir, has been associated with reports of clinical hepatitis and hepatic decompensation, including some fatalities. These have generally occurred in patients with advanced HIV disease taking multiple concomitant medications. A causal relationship to APTIVUS/ritonavir could not be established. All patients should be followed closely with clinical and laboratory monitoring, especially those with chronic hepatitis B or C co-infection, as these patients have an increased risk of hepatotoxicity. Liver function tests should be performed prior to initiating therapy with APTIVUS/ritonavir, and frequently throughout the duration of treatment.

Patients with chronic hepatitis B or hepatitis C co-infection or elevations in transaminases are at approximately 2.5-fold risk for developing further transaminase elevations or hepatic decompensation. Additionally, Grade 3 and 4 increases in hepatic transaminases were observed in 6% of healthy volunteers in Phase 1 studies and 6% of subjects receiving APTIVUS/ritonavir in Phase 3 studies.

Tipranavir is principally metabolized by the liver. Therefore caution should be exercised when administering APTIVUS/ritonavir to patients with hepatic impairment because tipranavir concentrations may be increased. APTIVUS/ritonavir is contraindicated in patients with moderate to severe (Child-Pugh Class B and Child-Pugh Class C) hepatic insufficiency.

Physicians and patients should be vigilant for the appearance of signs or symptoms of hepatitis, such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria, acholic stools, liver tenderness or hepatomegaly. Patients with signs or symptoms of clinical hepatitis should discontinue APTIVUS/ritonavir treatment and seek medical evaluation.

For information on the multi-dose pharmacokinetics of tipranavir in hepatically impaired patients (see **CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations, *Hepatic Impairment***).

Diabetes Mellitus/Hyperglycemia

New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-1 infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.

PRECAUTIONS

Sulfa Allergy

APTIVUS (tipranavir) should be used with caution in patients with a known sulfonamide allergy. Tipranavir contains a sulfonamide moiety. The potential for cross-sensitivity between drugs in the sulfonamide class and tipranavir is unknown.

Rash

Mild to moderate rashes including urticarial rash, maculopapular rash, and possible photosensitivity have been reported in subjects receiving APTIVUS/ritonavir. In Phase 2 and 3 trials rash was observed in 14% of females and in 8-10% of males receiving APTIVUS/ritonavir. Additionally, in one drug interaction trial in healthy female volunteers administered a single dose of ethinyl estradiol followed by APTIVUS/ritonavir, 33% of subjects developed a rash. Rash accompanied by joint pain or stiffness, throat tightness, or generalized pruritus has been reported in both men and women receiving APTIVUS/ritonavir (see **PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS**).

Patients with Hemophilia

There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis in patients with hemophilia type A and B treated with protease inhibitors. In some patients additional Factor VIII was given. In more than half of the reported cases, treatment with

